D

Darst Dermatology | Charlotte Office

Research site

(Unclaimed)

Location

11301 Golf Links Drive North, Suite 203, Charlotte, North Carolina, United States of America

Site insights

Top conditions

Top treatments

CTP-543

Guselkumab

ABBV-157

Cedirogant

CLS006

Eltrekibart

Ritlecitinib

Risankizumab

IMG-007

LY3041658

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 13 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Active, not recruiting

Stable Nonsegmental Vitiligo

Active Nonsegmental Vitiligo

Drug: Ritlecitinib

Drug: Placebo

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Active, not recruiting

Hidradenitis Suppurativa

Drug: Placebo

Drug: Eltrekibart

Locations recently updated

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis (ADAPTIVE)

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Enrolling

Atopic Dermatitis

Atopic Dermatitis Eczema

Drug: Placebo

Drug: IMG-007

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting

Alopecia Areata

Drug: CTP-543

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (UnlIMMited)

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Active, not recruiting

Scalp Psoriasis

Genital Psoriasis

Drug: Risankizumab

Drug: Placebo for Risankizumab